AbstractPurpose of review
This current work offers an opinion on the evidence accumulated in humans regarding stereotactic ablative radiation (SABR) therapy, a favorable option for the treatment of persistent or recurrent metastatic gynecologic cancers.Recent findings
SABR precisely and accurately kills cancer cells, making durable disease control possible. This article evaluates SABR's clinical performance and the variations in the main components of SABR technology, such as target localization and radiation beam collimation coupled with respiratory motion tracking, in the context of their contribution to the banked clinical successes in gynecologic radiation oncology.Summary
In an era of patient requests for short radiotherapy courses, SABR now provides well tolerated and efficacious treatment for women with gynecologic cancers.